Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma
Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma
Recruiting · NCT07377045 · Registry updated 2026-01-29Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma | Pancreatic Adenocarcinoma Metastatic | Recruiting | Phase 1 | 2026-01-29 | NCT07377045 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Oncomatryx Biopharma S.L. | 2 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beth Israel Deaconess Medical Center (Bidmc) | Boston | United States | 14 |
| Clinica Universidad de Navarra (CUN) | Pamplona | Spain | 3 |
| Hospital Clínico Universitario de Santiago - CHUS | Santiago de Compostela | Spain | 1 |
| Hospital Universitario 12 Octubre | Madrid | Spain | 4 |
| Hospital Universitario Donostia | Donostia / San Sebastian | Spain | 9 |
| Hospital Universitario Vall d'Hebron (VHIO) | Barcelona | Spain | 1 |
| ICO- Hospitalet Catalan Institute of Oncology | L'Hospitalet de Llobregat | Spain | 1 |